Avoiding overanticoagulation: Knowing your antibiotics

Thrombosis and Haemostasis

Volumn 88, Issue 5, 2002, Pages 703-704

  Baglin, Trevor ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; COUMARIN ANTICOAGULANT; DOXYCYCLINE; ERYTHROMYCIN; NEW DRUG; NORFLOXACIN; OFLOXACIN; PHENPROCOUMON; PRODRUG; THROMBIN INHIBITOR; TRIMETHOPRIM; UNCLASSIFIED DRUG; WARFARIN; XIMELAGOTRAN; ANTIINFECTIVE AGENT; COUMARIN DERIVATIVE;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNICABLE DISEASE; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; HEALTH CARE MANAGEMENT; HUMAN; NOTE; OVERANTICOAGULATION; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RISK FACTOR; THROMBOSIS; THROMBOSIS PREVENTION; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; INTOXICATION;

ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; COUMARINS; DRUG INTERACTIONS; HEMORRHAGE; HUMANS; OVERDOSE;

EID: 0036846680     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613288     Document Type: Note

References (12)

1. Visser L, Penning-van Beest F, Kasbergen A, et al. Overanticoagulation associated with combined use of antibacterial drugs and coumarin anti-coagulants. Thromb Haemost 2002; 88: 705-710.
2. Makris M, Watson HG. The management of coumarin-induced over-anti-coagulation. Br J Haematol 2001; 114 (2): 271-80.
3. van der Meer F, Rosendaal F, Vandenbroucke J, Briet E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993; 153: 1557-62.
4. Cannegieter S, Rosendaal F, Wintzen A, Van Der Meer F, Vandenbroucke J, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
5. Palareti G, Leali N, Coccheri S, et al Bleeding complications of oral anti-coagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
6. Eckman M, Levine H, Pauker S. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993; 329 (10): 696-702.
7. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991; 7 (4): 403-22.
8. Holbrook A, Wells P, Crowther N. Pharmacokinetics and drug interactions with warfarin. In: Poller L, Hirsh J, eds. Oral anticoagulants: Arnold, 1996: 30-48.
9. Mannucci P. Genetic control of anticoagulation. Lancet 1999; 353: 688-9.
10. Baglin T. Avoiding overanticoagulation: pharmacogenomics or pragmatism? Thromb Haemost 2001; 85 (5): 945-6.
11. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 2002; 57 (11): 751-8.
12. Hopfner R. Ximelagatran (AstraZeneca). Curr Opin Investig Drugs 2002; 3 (2): 246-51.